Skip to content

The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial.

The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial. - The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000045111
Enrollment
60
Registered
2021-08-10
Start date
2021-08-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Epi group : The epidural catheter is inserted between the 8th and 9th vertebrae. 100 ml of 0.25% levobupivacaine, 20 ml of fentanyl, and 80 ml of saline are infused continuously at 2-6 ml/hr. After co

Sponsors

SHOWA University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with esophageal cancer who are hospitalized or attending the Department of Gastroenterology and General Surgery, Showa University Hospital, and who have undergone radical thoracoscopic subtotal esophagectomy 2) Patients whose age at the time of consent acquisition is between 20 and 75 years old. 3) Patients who have given written consent to participate in this study.

Exclusion criteria

Exclusion criteria: (1) Patients with contraindications to the administration of levobupivacaine, fentanyl, or acetaminophen. (2) Patients who are at risk for epidural anesthesia catheter insertion or who have difficulty in insertion. (3) Patients who have difficulty in interviewing for postoperative pain assessment (dementia, postoperative intubation status, etc.). (4) Patients with serious hepatic, renal, or cardiac disorders that may affect the safety assessment of the drug. 5) Patients with additional painful procedures such as insertion of additional thoracic drains in the postoperative course, or with postoperative complications that affect postoperative pain. (6) Patients who have been administered anticoagulants before surgery. (7) Patients deemed ineligible by the research physician.

Design outcomes

Primary

MeasureTime frame
Numerical Rating Scale (NRS) at postoperative day 1 and 3 and 5.

Countries

Japan

Contacts

Public ContactTomotake Ariyoshi

SHOWA University General and Gastroenterological Surgery

tariyoshi@med.showa-u.ac.jp0337848541

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026